Literature DB >> 28278050

Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells.

Adnen Faddaoui1,2, Razan Sheta1,2, Magdalena Bachvarova2, Marie Plante2,3, Jean Gregoire2,3, Marie-Claude Renaud2,3, Alexandra Sebastianelli2,3, Stephane Gobeil1,4, Chantale Morin2, Karim Ghani2, Dimcho Bachvarov1,2.   

Abstract

Previously, we have identified the Grainyhead transcription factor 2 gene (GRHL2) as notably hypomethylated in high-grade (HG) serous epithelial ovarian tumors, compared with normal ovarian tissues. GRHL2 is known for its functions in normal tissue development and wound healing. In the context of cancer, the role of GRHL2 is still ambiguous as both tumorigenic and tumor suppressive functions have been reported for this gene, although a role of GRHL2 in maintaining the epithelial status of cancer cells has been suggested. In this study, we report that GRHL2 is strongly overexpressed in both low malignant potential (LMP) and HG serous epithelial ovarian tumors, which probably correlates with its hypomethylated status. Suppression of the GRHL2 expression led to a sharp decrease in cell proliferation, migration and invasion and induced G1 cell cycle arrest in epithelial ovarian cancer (EOC) cells displaying either epithelial (A2780s) or mesenchymal (SKOV3) phenotypes. However, no phenotypic alterations were observed in these EOC cell lines following GRHL2 silencing. Gene expression profiling and consecutive canonical pathway and network analyses confirmed these data, as in both these EOC cell lines, GRHL2 ablation was associated with the downregulation of various genes and pathways implicated in cell growth and proliferation, cell cycle control and cellular metabolism. Taken together, our data are indicative for a strong oncogenic potential of the GRHL2 gene in EOC progression and support recent findings on the role of GRHL2 as one of the major phenotypic stability factors (PSFs) that stabilize the highly aggressive/metastatic hybrid epithelial/mesenchymal (E/M) phenotype of cancer cells.

Entities:  

Keywords:  CRISPR/Cas9; GRHL2; cancer cell migration/invasion; epithelial ovarian cancer; epithelial-to-mesenchymal transition; microarrays; shRNA

Mesh:

Substances:

Year:  2017        PMID: 28278050      PMCID: PMC5397264          DOI: 10.1080/15384101.2017.1295181

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  68 in total

1.  Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

Authors:  Peyton T Taylor; Doris Haverstick
Journal:  J Natl Cancer Inst       Date:  2005-01-19       Impact factor: 13.506

Review 2.  Recent discoveries concerning the involvement of transcription factors from the Grainyhead-like family in cancer.

Authors:  Michal Mlacki; Agnieszka Kikulska; Ewa Krzywinska; Magdalena Pawlak; Tomasz Wilanowski
Journal:  Exp Biol Med (Maywood)       Date:  2015-06-10

3.  Integrative bioinformatics analysis reveals new prognostic biomarkers of clear cell renal cell carcinoma.

Authors:  Henriett Butz; Peter M Szabó; Roy Nofech-Mozes; Fabio Rotondo; Kalman Kovacs; Lorna Mirham; Hala Girgis; Dina Boles; Attila Patocs; George M Yousef
Journal:  Clin Chem       Date:  2014-08-19       Impact factor: 8.327

4.  Expression of transcription factor grainyhead-like 2 is diminished in cervical cancer.

Authors:  Luis A Torres-Reyes; Liliana Alvarado-Ruiz; Patricia Piña-Sánchez; María G Martínez-Silva; Moisés Ramos-Solano; Vicente Olimón-Andalón; Pablo C Ortiz-Lazareno; Georgina Hernández-Flores; Alejandro Bravo-Cuellar; Adriana Aguilar-Lemarroy; Luis F Jave-Suarez
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 5.  Transitions between epithelial and mesenchymal states in development and disease.

Authors:  Buzz Baum; Jeffrey Settleman; Margaret P Quinlan
Journal:  Semin Cell Dev Biol       Date:  2008-02-09       Impact factor: 7.727

6.  Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses.

Authors:  Robert Strauss; Pavel Sova; Ying Liu; Zong Yi Li; Sebastian Tuve; David Pritchard; Paul Brinkkoetter; Thomas Möller; Oliver Wildner; Sari Pesonen; Akseli Hemminki; Nicole Urban; Charles Drescher; André Lieber
Journal:  Cancer Res       Date:  2009-06-02       Impact factor: 12.701

7.  Transformation of cell adhesion properties by exogenously introduced E-cadherin cDNA.

Authors:  A Nagafuchi; Y Shirayoshi; K Okazaki; K Yasuda; M Takeichi
Journal:  Nature       Date:  1987 Sep 24-30       Impact factor: 49.962

8.  Mammary morphogenesis and regeneration require the inhibition of EMT at terminal end buds by Ovol2 transcriptional repressor.

Authors:  Kazuhide Watanabe; Alvaro Villarreal-Ponce; Peng Sun; Michael L Salmans; Magid Fallahi; Bogi Andersen; Xing Dai
Journal:  Dev Cell       Date:  2014-04-14       Impact factor: 12.270

9.  DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage.

Authors:  George S Watts; Bernard W Futscher; Nicholas Holtan; Koen Degeest; Frederick E Domann; Stephen L Rose
Journal:  BMC Med Genomics       Date:  2008-09-30       Impact factor: 3.063

Review 10.  Epithelial-mesenchymal plasticity in carcinoma metastasis.

Authors:  Jeff H Tsai; Jing Yang
Journal:  Genes Dev       Date:  2013-10-15       Impact factor: 11.361

View more
  13 in total

Review 1.  Grainyhead-like transcription factors in cancer - Focus on recent developments.

Authors:  Grzegorz Kotarba; Agnieszka Taracha-Wisniewska; Tomasz Wilanowski
Journal:  Exp Biol Med (Maywood)       Date:  2020-02-02

2.  GRHL2 Enhances Phosphorylated Estrogen Receptor (ER) Chromatin Binding and Regulates ER-Mediated Transcriptional Activation and Repression.

Authors:  Rebecca M Reese; Kyle T Helzer; Kaelyn O Allen; Christy Zheng; Natalia Solodin; Elaine T Alarid
Journal:  Mol Cell Biol       Date:  2022-08-29       Impact factor: 5.069

3.  CRISPR/Cas9-mediated double knockout of SRPK1 and SRPK2 in a nasopharyngeal carcinoma cell line.

Authors:  Pongphol Prattapong; Chawalit Ngernsombat; Sathid Aimjongjun; Tavan Janvilisri
Journal:  Cancer Rep (Hoboken)       Date:  2019-11-27

Review 4.  Grainyhead-like 2 as a double-edged sword in development and cancer.

Authors:  Jiaxing He; Chunyang Feng; He Zhu; Shuying Wu; Peng Jin; Tianmin Xu
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

5.  Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer.

Authors:  Edmond M Kwan; Heidi Fettke; Megan Crumbaker; Maria M Docanto; Sarah Q To; Patricia Bukczynska; Andrew Mant; Nicole Ng; Siavash Foroughi; Lisa-Jane K Graham; Anne-Maree Haynes; Sarah Azer; Lisi Elizabeth Lim; Eva Segelov; Kate Mahon; Ian D Davis; Phillip Parente; Carmel Pezaro; Tilman Todenhöfer; Niranjan Sathianathen; Christine Hauser; Lisa G Horvath; Anthony M Joshua; Arun A Azad
Journal:  Transl Androl Urol       Date:  2021-04

Review 6.  Complex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity in Ovarian Cancer.

Authors:  Yuliya Klymenko; Oleg Kim; M Sharon Stack
Journal:  Cancers (Basel)       Date:  2017-08-09       Impact factor: 6.639

7.  Numb prevents a complete epithelial-mesenchymal transition by modulating Notch signalling.

Authors:  Federico Bocci; Mohit K Jolly; Satyendra C Tripathi; Mitzi Aguilar; Samir M Hanash; Herbert Levine; José N Onuchic
Journal:  J R Soc Interface       Date:  2017-11       Impact factor: 4.118

8.  Hic-5 regulates epithelial to mesenchymal transition in ovarian cancer cells in a TGFβ1-independent manner.

Authors:  Razan Sheta; Zhi-Qiang Wang; Magdalena Bachvarova; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Stephane Gobeil; Chantale Morin; Elizabeth Macdonald; Barbara Vanderhyden; Dimcho Bachvarov
Journal:  Oncotarget       Date:  2017-07-31

9.  GRHL2 Upregulation Predicts a Poor Prognosis and Promotes the Resistance of Serous Ovarian Cancer to Cisplatin.

Authors:  Yanting Nie; Yiling Ding; Mengyuan Yang
Journal:  Onco Targets Ther       Date:  2020-06-30       Impact factor: 4.147

10.  The polypeptide GALNT6 Displays Redundant Functions upon Suppression of its Closest Homolog GALNT3 in Mediating Aberrant O-Glycosylation, Associated with Ovarian Cancer Progression.

Authors:  Razan Sheta; Magdalena Bachvarova; Elizabeth Macdonald; Stephane Gobeil; Barbara Vanderhyden; Dimcho Bachvarov
Journal:  Int J Mol Sci       Date:  2019-05-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.